Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?

Transl Lung Cancer Res. 2023 Jul 31;12(7):1631-1635. doi: 10.21037/tlcr-23-273. Epub 2023 Jun 12.

Authors

Shruti R Patel¹, Joel W Neal¹

Affiliation

¹ Division of Medical Oncology, Department of Medicine, Stanford University, Stanford Cancer Institute, Palo Alto, CA, USA.

No abstract available

Keywords: ADAURA; Osimertinib; adjuvant; epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC).

Publication types

Editorial
Comment